AD/PD 2025: First real-world data report for Leqembi focuses on operational challenges
Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases has (AD/PD) been on their real-world use.
Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases has (AD/PD) been on their real-world use.
What's Your Reaction?
